CLOT Conversations
Thrombosis Canada
0
CLOT Conversations is a podcast for healthcare professionals focused on the latest advances in thrombosis diagnosis and management. It is hosted by Dr Jameel Abdulrehman, a hematologist specializing in thrombosis and hemostasis at the University Health Network in Toronto, and David Airdrie, executive director of Thrombosis Canada. In short, digestible episodes, they discuss new research and the evolving field of thrombosis. The show is produced by Thrombosis Canada and points listeners to the organization's resources, tools, and programs for improving patient care and outcomes.
Episodes
-
OCEANIC-STROKE: Rethinking Secondary Stroke Prevention with Dr. Mike Sharma 11.09.2026 24mSend us Fan Mail For decades, antiplatelet therapy has been central to secondary prevention following noncardioembolic ischemic stroke. Could factor XIa inhibition offer another approach? Dr. Mike Sharma, principal investigator and first author of OCEANIC-STROKE, joins Dr. Maha Othman and Dr. Jameel Abdulrehman to discuss the phase 3 trial of asundexian for secondary stroke prevention. OCEANIC-STROKE randomized 12,327 patients with noncardioembolic ischemic stroke or high-risk TIA to asundexi... -
Acute PE: New Categories, Faster Decisions and What Changes in Practice 26.08.2026 32mSend us Fan Mail Dr. Lana Castellucci and Dr. Kerstin de Wit join CLOT Conversations to discuss the 2026 guideline for the evaluation and management of acute pulmonary embolism in adults and what its recommendations mean for clinical practice. The conversation explores the new A–E clinical categories for acute PE, including how to recognize patients whose condition may be deteriorating despite not meeting traditional criteria for high-risk PE. The discussion also covers the role of PE respons... -
EPCAT III: Is Aspirin Alone Enough After Hip or Knee Arthroplasty? 11.08.2026 19mSend us Fan Mail Is aspirin alone enough to prevent venous thromboembolism after total hip or knee arthroplasty? In this episode of CLOT Conversations, Dr. Jameel Abdulrehman speaks with Dr. Sudeep Shivakumar, lead author of the EPCAT III trial, recently published in the New England Journal of Medicine. EPCAT III randomized more than 5,400 patients undergoing hip or knee arthroplasty to receive aspirin alone or rivaroxaban for five days followed by aspirin. Dr. Shivakumar discusses the study'... -
Hormones, Clots, and Clinical Decisions with Dr Shannon Bates and Dr Leslie Skeith 17.06.2026 31mSend us Fan Mail Hormone therapy is used across a wide range of clinical settings—from contraception and menopause management to pregnancy care and gender-affirming therapy. But how do these treatments influence thrombosis risk, and how should clinicians approach these decisions in practice? In this episode of CLOT Conversations, hosts Dr. Jameel Abdulrehman and Dr. Maha Othman speak with Dr. Leslie Skeith and Dr. Shannon Bates about their recent New England Journal of Medicine review on sex ... -
C-TRACT Trial: Endovascular Therapy for Post-Thrombotic Syndrome with Dr. Susan Kahn 04.06.2026 23mSend us Fan Mail Post-thrombotic syndrome (PTS) affects up to half of patients following deep vein thrombosis and can significantly impair quality of life. Yet treatment options have historically been limited. In this episode of CLOT Conversations, David Airdrie and Dr. Jameel Abdulrehman speak with Dr. Susan Kahn about the recently published C-TRACT trial in The New England Journal of Medicine. The trial evaluated whether endovascular therapy, including iliac vein stenting, could improve out... -
Surgical and Procedural Bleed Risk Stratification in Anticoagulated Patients: ISTH Guidance in Practice 29.04.2026 29mSend us Fan Mail Perioperative anticoagulation management is a common and complex clinical challenge. In this episode of CLOT Conversations, Drs. James Douketis and Joseph Shaw discuss new ISTH guidance on surgical and procedural bleed risk stratification in anticoagulated patients. The discussion explores why updated guidance was needed, addressing inconsistencies in prior schemas, and introduces a more detailed, procedure-specific framework. The authors outline a three-tier classification—m... -
Which DOAC Bleeds Less? COBRRA Trial Insights for VTE Care with Dr Lana Castellucci 06.04.2026 16mSend us Fan Mail Which DOAC bleeds less in acute VTE? In this episode, we explore the COBRRA trial comparing apixaban vs rivaroxaban and what it means for clinical practice. The COBRRA trial provides the first direct, randomized comparison of apixaban and rivaroxaban for the treatment of acute venous thromboembolism (VTE). In this episode of CLOT Conversations, Dr. Lana Castellucci discusses findings from this landmark study and how they should influence anticoagulant selection. Key insights ... -
ARTESiA: Apixaban vs Aspirin Bleeding Risk with Dr D Siegal 18.02.2026 17mSend us Fan Mail Major bleeding remains the principal complication of oral anticoagulation. In patients with device-detected subclinical atrial fibrillation, the decision to anticoagulate requires careful balancing of stroke prevention against bleeding risk. In this episode of CLOT Conversations, Dr. Deborah Siegal discusses a prespecified subanalysis of the ARTESiA randomized clinical trial, recently published in JAMA Cardiology. ARTESiA demonstrated a 37% reduction in stroke and systemic em... -
WAVe Study: Cancer, Obesity, Anticoagulation with Dr Tzu-Fei Wang and Dr Gregoire Le Gal 16.12.2025 21mSend us Fan Mail Obesity presents a persistent challenge in the management of cancer-associated thrombosis, particularly when prescribing low molecular weight heparin beyond standard dose caps. In this episode of CLOT Conversations, host Dr. Jameel Abdulrehman is joined by Dr. Tzu-Fei Wang and Dr. Grégoire Le Gal to discuss findings from the WAVe study, a multicenter prospective cohort study evaluating weight-adjusted dalteparin dosing in patients over 90 kg with acute cancer-associated venou... -
ROXI-VTE Trials Explained: Dr. Jeff Weitz on Next-Generation Thrombosis Prevention 03.12.2025 22mSend us Fan Mail In this episode of CLOT Conversations, co-hosts Dr. Jamil Abdul-Rahman and Dr. Maha Othman have an in-depth discussion with leading thrombosis expert Dr. Jeff Weitz. Together, they unpack new findings from The Lancet on RGN-9933 and RGN-7508, two investigational factor XI inhibitors evaluated in the ROXI-VTE I and II phase-2 trials. These studies examine how targeted inhibition of factor XI may reduce post-operative venous thromboembolism with potentially lower bleeding risk ... -
Diagnosing the “Second Clot”: Lessons from PREDICTORS with Dr Vicky Mai and Dr Grégoire Le Gal 03.10.2025 17mSend us Fan Mail Diagnosing recurrent venous thromboembolism (VTE) remains one of the biggest clinical challenges in thrombosis medicine. In this episode, Dr. Vicky Mai and Dr. Grégoire Le Gal join us to discuss the international PREDICTORS study (JTH, 2025), which evaluated the performance of commonly used clinical decision rules (Wells and Geneva scores) in patients with suspected recurrent VTE. They share why symptoms can be misleading, how residual clots complicate imaging, and what their... -
Low Health Literacy in Pediatric Thrombosis: Clinical Risks and Realities - L. Avila and J. Vincelli 05.09.2025 15mSend us Fan Mail This episode reviews findings from a cross-sectional study at SickKids on health literacy in pediatric VTE patients and caregivers (Res Pract Thromb Haemost, 2025). Among 101 participants, 74% of adolescents and 59% of parents/caregivers demonstrated low general health literacy using REALM, HAS-A, and eHEALS instruments. Communication with providers was the most affected domain, and fewer than half of participants were satisfied with their thrombosis knowledge. Adolescents fr... -
Children and PE: Outcomes You Need to Know - L. Avila and J. Vincelli 28.08.2025 15mSend us Fan Mail In this episode, Dr. Laura Avila and Jennifer Vincelli discuss their Blood publication on long-term outcomes of pediatric pulmonary embolism. Among 150 patients, ~30% had incomplete PE resolution and 9% experienced recurrence, but persistent sequelae were rare. True post-PE syndrome occurred in <9%, with only one case of CTEPH. The findings highlight the value of structured follow-up, attention to underlying conditions, and promoting physical activity to counter deconditio... -
Navigating Thromboprophylaxis in Orthopedic Surgery 08.08.2025 12mSend us Fan Mail In this episode of CLOT Conversations, we discuss the newly developed Orthopedic Surgery VTE Thromboprophylaxis Guideline Summary. Dr. Marc Carrier, a hematologist and key author, highlights the need for a multidisciplinary approach in managing venous thromboembolism (VTE) risks, particularly in orthopedic surgery. The conversation covers preoperative risk assessments, options for pharmacological and mechanical thromboprophylaxis, and the evolving landscape of surgical techni... -
Risk Factors for Recurrent VTE in Cancer with Dr Faizan Khan 01.08.2025 19mSend us Fan Mail In this episode of CLOT Conversations, experts discuss recent research on cancer-associated thrombosis and the predictors of recurrent venous thromboembolism (VTE) and anticoagulant-related bleeding. Dr. Faizan Khan, a leading researcher in the field, explains the results of their study that aimed to offer a comprehensive understanding of the prognostic factors associated with these risks. Hear what he says about the evidence for associations of several patient- and cancer-re... -
Mapping Cancer's Hidden Risk—A Global Look at Blood Clots 24.07.2025 22mSend us Fan Mail Did you know that nearly 1 in 10 cancer patients worldwide may develop a potentially deadly blood clot? In this episode, we speak with researcher Jordan Harry, lead author of a landmark systematic review just published in Cancer Epidemiology, that uncovers which solid tumors carry the highest risk of venous thromboembolism (VTE) and where in the world patients are most vulnerable. Jordan walks us through surprising insights from their analysis of over 120 studies: 🔹 Why... -
INVENT VTE Dragons Den 17.07.2025 15mSend us Fan Mail In this episode we speak with the three competitors from the INVENT Dragons' Den competition 2025. Hear from the researchers about their research plans that they presented in the hopes of being awarded $40,000 in funding. The researchers were: Dr Francis Couturaud (ETHER Study), Dr Leslie Skeith (PARTUM Study) and Dr Emma Leitinger (BUTTERFLY Study). Participating INVENT network members include CanVECTOR (Canada), CURES Network (China), INNOVTE (France), INViTE (Ireland), DTN... -
The COBRRA Study: Shifting Paradigms in Acute VTE Treatment 27.06.2025 4mSend us Fan Mail In this episode of Clot Conversations, Dr. Lana Castellucci, University of Ottawa, discusses the COBRRA study, which compares the bleeding risks of rivaroxaban and apixaban in patients with acute VTE. The study follows patients for three months and finds that apixaban significantly reduces combined bleeding events compared to rivaroxaban. While the trial wasn't powered for individual outcomes, it shows no difference in VTE recurrence. This is potentially practice-changing inf... -
Breakthrough in DVT Diagnosis: Age-Adjusted D-Dimer Cutoff 27.06.2025 6mSend us Fan Mail In this episode of CLOT Conversations, Dr. Gregoire Le Gal, University of Ottawa, in an interview with Dr Vicky Mai, shares insights from his groundbreaking study on age-adjusted D-dimer cutoffs for diagnosing deep vein thrombosis (DVT). Previously validated for pulmonary embolism (PE), this new approach significantly improves DVT diagnostics. By adjusting D-dimer thresholds based on patient age, the study found a safe and reliable method to rule out DVT without reliance on a... -
COPD-PE Diagnosis & Recurrent VTE with Dr Vicky Mai 27.06.2025 7mSend us Fan Mail In this podcast episode, we explore groundbreaking research presented at the ISTH 2025 in Washington. Dr. Vicky May, Institut Universitaire de Cardiologie et Pneumologie de Québec, shares insights into a new diagnostic algorithm for pulmonary embolism (PE) in patients with chronic obstructive pulmonary disease (COPD). Her work focuses on identifying specific predictors, integrating these with established testing methods, and addressing challenges in the validation process. Th...
Popular in
The podcast also appears in the podcast charts of these countries.